📰 STAT News · 90
United StatesSTAT+: Up and down the ladder: The latest comings and goings
The article discusses recent personnel changes in the pharmaceutical industry, highlighting Jae Kim's appointment as chief medical officer at Protego Biopharma. It invites readers to submit their own updates on hiring and promotions.
Luigi Mangione Defense Abandons Controversial Courtroom Tactic
Luigi Mangione's legal team has abandoned a proposed psychiatric defense of 'extreme emotional disturbance' for his upcoming trial in the murder of UnitedHealthcare CEO Brian Thompson. The defense had been expected to be a key part of Mangione's strategy, but court filings indicate the team has formally withdrawn the tactic without providing an explanation. The decision follows a statement by Manhattan Supreme Court Justice Gregory Carro that Mangione intended to claim he was emotionally disturbed at the time of the killing. A successful such defense would have reduced a potential murder.conv.
Federal grant delays could jeopardize essential disability services, research
Federal funding delays threaten essential disability services and research, according to experts like Robert Gould, director of research for the Great Lakes ADA Center. The Chicago-based center, part of a national network providing support under the Americans with Disabilities Act, faces an August 31 deadline for its current funding. Researchers nationwide express concern over delayed grants from the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR), which is the sole federal entity dedicated to disability research.
Opinion: STAT+: The real work for making dramatic gains against pancreatic cancer is just beginning
An article discusses recent advancements in treating pancreatic cancer, highlighting a new drug, daraxonrasib, which showed improved survival rates in patients compared to traditional chemotherapy. The FDA granted early access to the drug for select patients who had exhausted other treatment options. The piece emphasizes the significance of these developments and the ongoing efforts needed to make substantial progress in combating pancreatic cancer.
Tennessee pharmacies sell potent ivermectin, led by anti-vaccine doctor who’s taken ‘bucketloads’
Tennessee allows pharmacies to sell ivermectin without a prescription using a pre-written blanket prescription. The drug, approved by the FDA for parasitic infections, has been heavily marketed in the state despite clinical evidence showing it is ineffective against COVID-19. Ivermectin has gained popularity among conservative groups and anti-vaccine advocates, including supporters of Robert F. Kennedy Jr.'s 'Make America Healthy Again' movement. Some pharmacies sell highly concentrated versions of the drug, sometimes at 10 or 20 times the standard potency.
Opinion: Maternity deserts aren’t accidents. They’re the result of a design flaw
The article discusses the growing issue of 'maternity deserts' in the United States, particularly in rural areas, where pregnant women face significant challenges accessing essential obstetric care due to a shortage of trained healthcare professionals. Despite declining fertility rates, the availability of maternity care is decreasing, especially in states like South Dakota, which lacks local training programs for obstetricians and relies heavily on imported doctors who often do not stay in rural areas long-term.
STAT+: FDA advisory panel endorses Moderna mRNA flu vaccine that was subject of controversy
An FDA advisory panel has endorsed Moderna's mRNA flu vaccine after it faced controversy earlier this year when a top agency official initially resisted considering it for review. The panel voted unanimously that the benefits of the vaccine outweigh the risks for adults aged 50 to 64 and those 65 and older. The FDA is expected to make a decision soon, with staff presentations suggesting the vaccine could be licensed through a traditional pathway for the younger group and an accelerated pathway for the older group. A former FDA employee who now works for Moderna commented on the situation.
Opinion: AI’s growing appetite for power is a public health issue. Here’s a fix
The article discusses the increasing energy demands of artificial intelligence (AI), particularly focusing on the impact of large data centers on electricity and water resources. It highlights concerns about rising electricity costs, environmental effects, strain on aging infrastructure, and potential health risks associated with these developments. The authors argue that reliable electricity is essential for public health and call attention to the need for addressing these challenges.
STAT+: CMS recalculates Medicare Advantage star ratings again, adding more volatility to program
Federal officials have recalculated the quality ratings for 2026 Medicare Advantage plans following legal challenges from health insurance companies. The recalculations come amid ongoing disputes over the $16 billion Medicare Advantage star rating system, which determines bonus payments for plans achieving at least four out of five stars. Insurers have previously challenged lower ratings, leading to previous recalculations. This year’s bonuses have grown significantly, reaching nearly the full budget of the CDC.
Africa CDC Warns Congo Ebola Outbreak Could Be Worst in History
Jean Kaseya, director of the Africa Centers for Disease Control (Africa CDC), warned that the ongoing Ebola outbreak in the Democratic Republic of the Congo (DRC) could become the worst in history if containment efforts fail. He noted that many individuals exposed to the virus remain untraced and untested. While the current outbreak has resulted in 782 cases and 181 deaths, health officials believe the actual numbers may be significantly higher due to challenges in diagnosis and tracking, including political instability and resistance from local populations. The outbreak, officially declared a
STAT+: Eli Lilly ends 340B drug discounts to some hospitals for failing to provide claims data
Eli Lilly has begun ending 340B drug discounts for certain hospitals that failed to provide comprehensive claims data, as part of a policy aimed at reducing duplicate discounts. The company stated that over 2,300 hospitals have complied with its request, while some larger hospital systems have not. Hospital trade groups argue the action is unlawful and seek congressional intervention.
STAT+: Do wearables actually help people with cardiovascular disease?
The article discusses whether wearable devices are effective in helping individuals with cardiovascular disease. The full text of the article is not available as it requires subscription to STAT+. The summary provided does not include specific findings or conclusions from the article.
STAT+: In pancreatic cancer, Patrick Soon-Shiong makes promises he has not kept
The article discusses Patrick Soon-Shiong, a billionaire physician and entrepreneur, and critiques the disparity between his public claims about his cancer treatments and the actual clinical outcomes supported by evidence. The piece highlights concerns regarding the efficacy of his cancer drugs, particularly in the context of pancreatic cancer, and references regulatory actions such as FDA interventions.
STAT+: Shingles vaccine may lower dementia risk, new study finds
A new study suggests that vaccination against shingles may reduce the risk of dementia among elderly individuals. Researchers found that nursing home residents who received at least one dose of the Shingrix vaccine were 24% less likely to develop dementia over four years compared to unvaccinated residents. The findings were published in the peer-reviewed journal Annals of Internal Medicine.
How many Americans can afford high-quality health care? A new poll finds the number has fallen
A new report from the West Health-Gallup Affordability Index indicates that only about half of U.S. adults could afford their health care and had access to quality care in 2024. The findings highlight growing concerns among Americans about the affordability of health care, with worries about future costs reaching a record high. The study is based on a survey conducted between October and December 2025, prior to recent changes in health policy such as Medicaid cuts.
RFK Jr. presents $700 million in mental health funding, but experts say grants aren’t new
The Trump administration announced $700 million in 'new funding' for mental health and addiction programs, emphasizing efforts to combat homelessness linked to untreated mental illness. However, experts argue that the funds are not new but rather delayed existing grants authorized by Congress. The Substance Abuse and Mental Health Services Administration (SAMHSA) had postponed the release of these grants, causing concern among state and local agencies reliant on federal funding. During an event in Clinton, Michigan, Health and Human Services Secretary Robert F. Kennedy Jr. described the funds,
The power decisions that could shape the next century
The article discusses the impact of AI-driven power demands on the U.S. electricity system, highlighting the need for major decisions regarding infrastructure growth. It notes that data centers are consuming large amounts of electricity, comparable to entire cities, which raises questions about cost distribution, access, and grid connectivity. The piece outlines ongoing debates at key regulatory bodies like PJM and the Federal Energy Regulatory Commission, including proposals for data centers to connect directly to power plants or generate their own power. These decisions are expected to have远
Super-potent synthetic opioids called nitazenes are spreading across the U.S.
Ashley Delgado, a former high-achieving student with aspirations of becoming a doctor, struggled with opioid addiction after being prescribed OxyContin following a leg injury. Her addiction progressed through various substances, including methamphetamine, heroin, and eventually fentanyl. Despite entering rehabilitation and living in a sober home, she died of an accidental overdose in 2023. Toxicology reports indicated the presence of protonitazene and metonitazene, which are potent synthetic opioids belonging to the nitazene class. Her father, James Taylor, expressed grief over losing his only
Opinion: Congress should embrace strategic health diplomacy
The article argues that Congress should prioritize global health as a key component of U.S. foreign policy, citing past successes like PEPFAR (President's Emergency Plan for AIDS Relief). The authors, former U.S. senators, highlight how investments in global health improve both international relations and U.S. national security. They emphasize the need for clear goals, long-term commitment, and preparedness in responding to global health crises.
Nara Organics recalls baby formula sold at Target after multistate infant botulism outbreak
Nara Organics has recalled its organic baby formula sold at Target and online following a multistate outbreak of infant botulism. Three infants between 2 and 5 months old fell ill after consuming the product, according to the U.S. Food and Drug Administration (FDA). The affected babies were hospitalized and treated with BabyBIG, an FDA-approved treatment for infant botulism. The illness is rare but severe, typically affecting babies under 1 year old due to their developing gut microbiomes. Symptoms include constipation, poor feeding, drooping eyelids, weak muscle tone, and breathing issues. Ná
Medicare weight-loss drug coverage could overwhelm doctors
The upcoming Medicare program offering weight-loss drugs at a reduced cost ($50 per month) is anticipated to significantly increase demand for medications like Wegovy and Zepbound. This surge in demand raises concerns among healthcare providers about potential bottlenecks in accessing these treatments, as well as challenges in providing adequate patient counseling regarding proper usage, dosage adjustments, and managing side effects. The program stems from a deal between former President Donald Trump and pharmaceutical companies Eli Lilly and Novo Nordisk, aimed at reducing drug prices in lieu
STAT+: Abridge inks deals with Nvidia and Lilly
Health care AI company Abridge has formed new partnerships with pharmaceutical giant Eli Lilly and chipmaker Nvidia. The collaborations aim to enhance Abridge's platform, which assists clinicians with documentation and decision-making during patient visits. Abridge, already used by numerous health systems, showcased updates to its software at an event in New York.
STAT+: DOJ’s swift win in OhioHealth case should have hospitals studying their contracts, experts say
The Department of Justice (DOJ) has reached a proposed antitrust settlement with OhioHealth, a nonprofit hospital system, requiring it to stop using certain contracting practices that allegedly hindered health insurers from offering lower-cost policies. Legal experts suggest this swift resolution could prompt other hospitals to review their own contracts. The lawsuit, filed in February, accused OhioHealth of inflating prices through these practices.
FTC, four state AGs sue transgender health group over care standards
The Federal Trade Commission (FTC) and four state attorneys general from Alaska, Iowa, Nebraska, and Texas have filed a lawsuit against the World Professional Association for Transgender Health (WPATH). They allege that WPATH made false claims about the benefits and risks of gender-affirming care for minors, misleading children and parents. WPATH has denied the allegations, stating that the FTC lacks jurisdiction over their non-commercial speech and that the claims have factual and legal flaws. The lawsuit was filed in the Northern District of Texas, known for its conservative leaning.
NIH diversity programs doubled undergraduates’ odds of getting a Ph.D., 20-year study finds
A 20-year study published in Science Advances found that NIH-funded diversity programs, RISE and MARC, doubled the chances of undergraduate students earning a Ph.D. These programs were established under the NIH Revitalization Act of 1993 to increase participation of underrepresented minorities in biomedical and behavioral research. However, both programs were terminated by the Trump administration in recent years.
World model maker Odyssey nabs $1.45B valuation backed by Amazon and other big names
Odyssey, a world model AI startup founded by former self-driving vehicle executives, has raised $310 million in a Series B funding round at a $1.45 billion valuation. The round was led by Natural Capital, with participation from Amazon, AMD Ventures, GV, and others. Odyssey uses real-world data to create simulations with accurate physics, similar to how Google Earth gathers information. The company offers world models for various applications, including video game development and robotics. With Amazon's support, Odyssey plans to optimize its models for AWS's Trainium chips.
I Thought We’d Found a Fix for My Daughter’s School Problem. Now We’re Back at the Start—and Out $5,000.
A parent writes about their frustration after their 13-year-old daughter initially agreed to attend a private school but now wants to be homeschooled instead. The parent had invested significant time and $5,000 in securing a spot at the private school, which they felt was necessary due to their daughter's unhappiness at her current school. The parent is upset about the financial loss and effort spent, while their spouse believes the $5,000 should be considered a 'sunk cost' and suggests moving forward with homeschooling.
STAT+: Advocacy groups petition FDA to withdraw approval of ‘unsafe’ use of antibiotics given to livestock
Over 60 advocacy groups have submitted a petition to the FDA requesting the withdrawal of approval for the 'unsafe' use of antibiotics in livestock to prevent disease. The groups argue that the widespread use of antibiotics in animal farming contributes to antibiotic resistance, which poses serious risks to public health, including approximately 35,000 deaths and over 2 million illnesses annually in the U.S. One of the petitioners, Peter Lehner from Earthjustice Sustainable Food and Farming, stated that the FDA is obligated to ensure that animal drugs do not harm humans and criticized the FDA
STAT+: FDA approves Colorado’s plan to import cheaper drugs from Canada
The FDA has approved Colorado's plan to import prescription drugs from Canada in an effort to reduce medication costs for residents. This makes Colorado the second U.S. state to receive such authorization after Florida. The practice of importing drugs from Canada has been ongoing for over 25 years, but formal regulatory support only began under the Trump administration in 2020, with the Biden administration affirming the policy through an executive order in 2021.
STAT+: Pharmalittle: We’re reading about hackers extorting Novo, an FDA about-face, and more
A cyber extortion group called FulcrumSec claims to have stolen over a terabyte of data from Novo Nordisk, including source code, drug development information, and internal AI models. The group reportedly spent over two months inside the company's network before failing to secure a $25 million ransom. Additionally, the U.S. Food and Drug Administration has reversed its stance on a controversial experimental treatment.
STAT+: Is Abridge’s ‘patient centered’ claim a bridge too far?
The article discusses concerns regarding Abridge, a health technology company, and whether its 'patient-centered' approach is overreaching. The piece appears to be part of a larger newsletter focusing on artificial intelligence in healthcare, specifically examining the effectiveness and ethical implications of such technologies.
Trump administration will bring special ed to HHS
The Trump administration has announced plans to transfer oversight of special education from the Department of Education to the Department of Health and Human Services (HHS), as outlined in Project 2025, a policy blueprint developed by the Heritage Foundation. This move is part of broader efforts to eliminate the Education Department. Advocates for people with disabilities have expressed concern over the shift, citing potential implications for the management of disability education programs.
Opinion: How STAT decided to keep ‘health care’ as two words
STAT News discusses its decision to retain 'health care' as two words despite the Associated Press Stylebook's shift to 'healthcare' as one word. The article highlights the significance of the term for STAT's identity and coverage, with input from Sarah Mupo, STAT's director of editorial operations.
Opinion: As a physician, I have never been more concerned about rates of congenital syphilis
A physician and former public health official expresses concern over rising rates of congenital syphilis in the United States, citing data from the Centers for Disease Control and Prevention (CDC). The article notes that nearly 4,000 new cases were reported in 2024—the highest since the mid-1950s—and highlights that many affected infants suffer lifelong disabilities or developmental delays. The author attributes the rise to the decline in public health infrastructure beginning during the Great Recession and subsequent underfunding of local public health programs. The article emphasizes that a
Opinion: The quiet joy of being an oncologist
An oncologist reflects on the emotional impact of delivering positive medical news to patients and their families, highlighting the profound sense of relief and hope that can come from such moments. The author acknowledges the challenges and emotional weight of working in oncology but emphasizes the deep fulfillment found in these rare instances of joy.
STAT+: A prominent VC explains why she’s against U.S. restrictions on investment in China’s drug industry
The article discusses the debate over whether the U.S. government should impose restrictions on investments in China's biotech industry. Venture capitalist Julie Grant argues against such measures, suggesting they would hinder U.S. drug development and harm patients. The discussion comes amid efforts by some legislators to expand the scope of the COINS Act to include biotechnology.
STAT+: How a biotech turned a trial failure into an AI model
The article discusses how a biotechnology company transformed a failed trial into an AI model, though the full details of the story are behind a paywall and not accessible in the provided text.
US infant mortality rate fell to an all-time low, but still trails similar nations
According to preliminary government data from the Centers for Disease Control and Prevention, the U.S. infant mortality rate dropped to a new all-time low in 2025, with approximately 5.4 infant deaths per 1,000 live births. This represents a slight decrease from previous years and is considered statistically significant, potentially translating to hundreds of fewer infant deaths annually. Researchers note that while the exact reasons behind the decline are unclear, they view the trend positively. The overall number of infant deaths also decreased compared to prior years, though the final count
Covid vaccination cut risk of adverse heart events, large study finds
A recent study published in JAMA Internal Medicine found that recent COVID vaccination reduces the risk of adverse heart events such as heart attacks, strokes, hospitalizations, and death. The research followed over 1 million U.S. veterans who received flu vaccinations at VA healthcare facilities in 2024, with about a third also receiving a COVID vaccine. The study found a 38% lower risk of major cardiovascular events associated with COVID among vaccinated individuals, particularly benefiting those aged 75 and older and those with chronic conditions. Additionally, there was a 24% reduction in
STAT+: Verge Labs’ new AI model solves patient stratification problems for neurology clinical trials
Verge Labs, a biotechnology company founded by Alice Zhang, developed an AI model aimed at improving patient stratification for neurology clinical trials. The company previously focused on identifying genetic networks linked to neurodegenerative diseases such as Parkinson’s, ALS, and Alzheimer’s. While Verge Genomics identified promising drug targets, including two selected by Eli Lilly for their pipeline, its recent Phase 1b trial for an ALS drug failed due to high patient dropout rates caused by intolerance to the treatment. The company has shared insights from this failure to benefit future
STAT+: Pharmalittle: We’re reading about Medicare and obesity drugs, Germany’s pricing plans, and more
The article discusses the availability of weight loss drugs under Medicare for adults aged 65 and older starting next month through a temporary government program. The Trump administration is using a demonstration program to bypass existing laws prohibiting Medicare from covering obesity drugs. The article also mentions Germany's pricing plans for medications and other related topics.
How supplement use changed over decades
This article discusses changes in supplement use over decades, though the provided text appears to focus on unrelated topics such as contraceptive storage costs and Medicare-covered weight loss medications. The article references a USAID report on the financial burden of storing unused contraceptives intended for international aid, as well as upcoming Medicare coverage for GLP-1 weight loss drugs.
Opinion: Congress must reauthorize the Pandemic and All-Hazards Preparedness Act
Two former officials involved in the creation of the Pandemic and All-Hazards Preparedness Act (PAHPA) argue that Congress should reauthorize the law and confirm the Trump administration's nominee for the assistant secretary position at the Administration for Strategic Preparedness and Response (ASPR). They highlight ASPR's role in coordinating responses to health emergencies and note recent events emphasizing the importance of maintaining this agency.
Opinion: I’m an Alzheimer’s specialist. I still missed it in my own father
The author, Elizabeth Bevins, a neurologist specializing in Alzheimer's disease, reflects on her experience of recognizing her father's early symptoms of Alzheimer's. She describes how her father's cognitive decline was initially dismissed due to his busy schedule and his ability to perform well on standard cognitive tests. Despite her expertise, she only realized the severity of his condition when she observed his confusion upon meeting her newborn daughter. The article highlights the challenges of diagnosing Alzheimer's early and the limitations of current diagnostic tools.
STAT+: Human Cell Atlas leader’s tie to 10x Genomics raises conflict-of-interest questions
The International Human Cell Atlas Consortium is holding a major conference in Boston, highlighting advancements in mapping human cell types. The consortium is preparing to release a first draft of its atlas, focusing on healthy cells and planning future research into disease-related cellular interactions. The article notes the involvement of key figures such as Aviv Regev, David Altshuler, and Eric Lander, while also mentioning the role of biotechnology firms like 10x Genomics in providing essential tools for the project.
STAT+: Trump’s obesity drug plan creates a temporary Medicare program that may be hard to end
The Trump administration is implementing a temporary Medicare program to provide weight loss drugs to adults aged 65 and older, bypassing existing laws that prohibit Medicare from covering obesity medications. Initially, Medicare planned to encourage private insurers to cover these drugs through a three-year program called BALANCE, but insurers resisted. As a result, the government has extended a transitional coverage program called Bridge until the end of next year.
STAT+: A key European clinical trial registry lacks complete and timely results, an analysis finds
A new analysis reveals that less than half of the studies registered in a key European clinical trial registry had results reported within the required timeframe, and only 42% provided full results. While the registration data quality was high, compliance with legal reporting requirements was found to be weak, and regulatory oversight is lacking. The findings were published on the medRxiv preprint server.
STAT+: Lilly’s Ajax acquisition may have been worth it
The article discusses recent developments in biotechnology, including a syphilis drug shortage affecting pregnant women in Arizona, the FDA's approval of Sanofi's diabetes drug Tzield following a contentious review, and the Trump administration's proposal to close a Medicare negotiation loophole.
FDA approves first new sunscreen ingredient in more than 20 years
The FDA approved bemotrizinol as a new sunscreen ingredient, marking the first addition to the list of permitted active ingredients since the late 1990s. The ingredient offers protection against both UV A and B rays and has low skin absorption. The FDA deems it safe and effective for use in sunscreens by adults and children aged six months and older. HHS Secretary Robert F. Kennedy Jr. stated the approval advances innovation in the sunscreen market. The decision aligns with a September report from the Trump administration’s Make America Health Again Commission, which recommended promoting FDA-
Opinion: In many South Asian American families, a child’s autism diagnosis is a secret
This opinion piece by Ritu Goel, a child and adolescent psychiatrist and founder of MindClaire PC, discusses the underdiagnosis of autism among South Asian American children due to cultural stigma. Goel highlights that while the CDC reports rising autism rates in the U.S., South Asian families often keep such diagnoses private. She notes that South Asian children are typically diagnosed later than white children and face barriers to accessing services, primarily due to societal stigma rather than factors like language, insurance, or geography.
STAT+: Amid confusion over Pfizer’s emergency penicillin program, newborn is diagnosed with preventable syphilis
A newborn in Gila County, Arizona, was diagnosed with syphilis after his mother was unable to receive timely penicillin treatment due to a nationwide shortage of the drug Bicillin L-A. The article details the confusion surrounding Pfizer's emergency penicillin program and highlights the challenges faced by healthcare providers in accessing the medication.
As states follow Trump’s Medicaid fraud playbook, people with disabilities struggle to find care
Jennifer Kucera, a person with spinal muscular atrophy, recounts traumatic experiences at a nursing home and fears returning there due to potential changes in Ohio's Medicaid regulations aimed at curbing fraud. These changes include a temporary halt on new home care providers and stricter eligibility criteria for both recipients and providers of Medicaid-funded care. The policy shift follows an investigation by the conservative news outlet the Daily Wire, which highlighted concerns about Medicaid fraud.
"American Diabetes Association Ejects Researchers from Conference for Sharing Editorial from Its Own Journal"
Researchers were removed from an American Diabetes Association (ADA) conference after distributing a printed editorial from the association's own journal, which criticized Trump administration policies on biomedical research. The researchers included the journal's editor, who co-authored the piece. They were escorted out by security at the request of the event organizers. The article raises concerns about the ADA's response to the distribution of its own publication and questions whether the organization's actions align with its stated commitment to open dialogue and diverse perspectives.
STAT+: FDA approves Sanofi diabetes drug for children with stage 3 diabetes
The FDA has approved teplizumab, a type 1 diabetes drug developed by Sanofi, for children aged 8 and older with stage 3 diabetes. The approval process involved a speedy review program initiated by former FDA Commissioner Marty Makary. However, the FDA missed its target decision date of April 21. Sanofi had requested to withdraw its drug from the program following disagreements between former top drug regulator Tracy Beth Høeg and staff regarding the approval decision. It is uncommon for a center director, especially a political appointee like Høeg, to participate directly in individual drug审批s
Opinion: ‘I’m pretty much all in’: An interview with a woman starting medical residency at almost 73
The article introduces an interview with Dawn Zuidgeest-Craft, a woman who is beginning medical residency at nearly 73 years old. The piece discusses her journey through medical school later in life and highlights her perspective on pursuing such a demanding career at an advanced age.
STAT+: Trump administration revisits policy to close Medicare drug price negotiation loophole
The Trump administration has proposed changes to a policy aimed at preventing pharmaceutical companies from circumventing Medicare price negotiations by adding new active ingredients to existing drugs. This policy is part of an annual rulemaking process by the Centers for Medicare and Medicaid Services (CMS), which determines the next 20 drugs and biologics eligible for price negotiation. The selected drugs will be announced by February 1, 2027, with negotiated prices taking effect in 2029. A similar proposal was considered last year but delayed for further study. Medicare generally waits 7 to
STAT+: Up and down the ladder: The latest comings and goings
The article announces a new hiring at AstronauTx, where Michelle Mellion has been appointed as chief medical officer. It notes her previous roles at PepGen and EveryONE Medicines. The piece invites readers to submit their own personnel changes for potential publication.
Nonprofit buys experimental cancer drug to maintain patient access
Nonprofit organization Blood Cancer United has purchased the remaining supplies of Luvelta, an experimental cancer drug that was discontinued by its developer, Sutro Biopharma. The nonprofit will manage the drug’s compassionate-use program, providing it to children with a rare form of blood cancer at no cost while supplies last. Sutro Biopharma decided to stop developing Luvelta in March 2025 to focus on other projects.
Chile offers new data on food warning label efficacy
The article mentions that Chile has provided new data regarding the effectiveness of food warning labels. However, the full content of the article is not available, as it appears to be truncated.
College Can Be Where Life Starts. Now It’s About Ending It.
The article discusses the availability of abortion pills on college campuses across the United States, noting that some institutions provide these medications due to state laws. It explains the process of medication abortions using mifepristone and misoprostol, referencing data from Planned Parenthood and statistics on the prevalence of pill abortions in 2023. The article highlights concerns about the lack of support for students undergoing this procedure and references actions taken by the Colorado legislature.
STAT+: At hospital finance conference, a call to end the friction that’s keeping costs high
At a recent hospital finance conference, the presence of numerous billing and collections companies highlighted the complex and costly nature of healthcare financing in the United States. The event focused on improving affordability and simplifying the billing process, despite the large industry dedicated to extracting payments from insurers.
Opinion: I’ve spent 40 years in research. I have never seen a threat to science like the new grantmaking rule
The author, with four decades of experience in research, expresses concern over a new federal grantmaking rule that they believe threatens the integrity of American scientific research. They highlight past achievements such as advancements in childhood leukemia treatment, cancer immunotherapy, genetic disease repair, GPS, semiconductors, and the internet, which were all products of U.S. scientific innovation. The author argues that the proposed changes to the grant system are unnecessary and could undermine future progress.
Diabetes association leader apologizes for expulsion of members, pledges to rebuild trust
The American Diabetes Association (ADA) CEO, Charles Henderson, issued an apology to five members who were expelled from the organization's annual scientific sessions in New Orleans for distributing an editorial critical of federal research funding cuts. The editorial, published in an ADA journal, expressed concerns over reduced funding and changes to the grant-making process at the National Institutes of Health (NIH). The original keynote speaker, NIH Director Jay Bhattacharya, withdrew from the event, and NIH senior adviser Richard Woychik spoke in his place. Henderson emphasized the ADA's继续
STAT+: Updated: Tracking RFK Jr.’s promises to remake health in America
The article tracks Robert F. Kennedy Jr.'s efforts to implement his promises as U.S. health secretary, noting both achievements and unmet goals across areas such as additives, chronic disease, and vaccines. The piece highlights Kennedy's claim of driving progress on various initiatives.
STAT+: An obesity drug deep-dive, and peptides move mainstream
This article introduces two STAT contributors, Elaine and Adam, and outlines topics covered in the latest episode of 'The Readout Loud,' a biotech podcast. The episode discusses new obesity medications, recent developments in the biotech industry, and the journey of the peptide BPC-157 from a Croatian lab to the FDA. Guest contributor Sara Talpos is mentioned for her reporting on BPC-157.
RFK Jr. claims his calendar is publicly available. We’ve been trying to get it for a year
Health Secretary Robert F. Kennedy Jr. claimed his calendar is 'publicly available' in response to criticism about transparency. However, STAT News has attempted to obtain his calendar through Freedom of Information Act requests and direct inquiries for over a year without success. The article highlights discrepancies between Kennedy's public commitments to transparency and the actual availability of information, noting legal challenges, reduced staffing for FOIA requests, and allegations of journalist blacklisting within the Department of Health and Human Services.
Drinking during pregnancy rose after 2020, new CDC data suggest
New CDC data indicate an increase in alcohol consumption among pregnant women in the United States between 2021 and 2024, compared to earlier years. The report highlights that 15% of pregnant women reported drinking within the last 30 days during this period, up from 13.5% between 2018 and 2020. The findings emphasize that alcohol use during pregnancy remains a significant public health concern, particularly among unmarried women and those experiencing mental distress. The report suggests that both clinical and community-based interventions could address this issue.
Study highlights influence of socioeconomic status on children’s brain development
A study published in Science analyzed brain scans from nearly 12,000 children aged 9 and 10 and found that socioeconomic status (SES) is the leading environmental factor influencing brain structure and function. Factors such as household income and neighborhood poverty levels accounted for approximately 16% of the variability in children's brain function. The research suggests that SES has a greater impact on neural development than factors like IQ, parenting style, or health history.
STAT+: A suspicious denial pattern in Medicare Advantage
The article discusses a follow-up report by Casey Ross and Bob Herman on how large Medicare Advantage insurers use artificial intelligence to override clinicians' judgments and deny care to seriously ill older and disabled patients.
STAT+: Novartis doubles down on molecular glue strategy
The article discusses recent developments in the biotechnology sector, including Novartis' continued investment in its molecular glue strategy, early data on Enliven's leukemia drug, and SonoThera's fundraising for an ultrasound-based gene delivery method. It also mentions rising Medicare drug costs linked to increased use of GLP-1 medications and policy changes.
STAT+: Novo underwhelmed by drug it once fought Pfizer for
The article discusses various developments in the biotechnology sector, including challenges in paying for gene therapies, Novo's reduced enthusiasm for an obesity drug, Incyte's investment in blood disease research, and competition among obesity treatments. It also mentions Roche's partnership with Nurix Therapeutics for a potential blood cancer treatment and Revolution Medicines' promising results with a pancreatic cancer drug.
STAT+: Private Medicare plans erect barriers to rehab care in pursuit of profit, federal investigators find
Federal investigators found that private Medicare Advantage insurers, including UnitedHealth Group and Humana, denied rehabilitative care to older and disabled Americans at higher rates than industry peers. These denials were frequently overturned when patients appealed. The insurers used a UnitedHealth subsidiary, NaviHealth, which employs AI to assess care needs. A previous STAT investigation highlighted issues with NaviHealth's denials leading to poor patient outcomes. According to the Office of Inspector General, insurers reversed NaviHealth's denials of nursing home care 97% of the time.
STAT+: Your sepsis algorithm shouldn’t require a time machine
The article discusses a sepsis prediction algorithm used in healthcare, highlighting concerns that such algorithms may rely on historical data that is no longer applicable, effectively requiring a 'time machine' to function accurately in real-time scenarios.
OB-GYN association, deviating from CDC guidance, issues its own vaccine recommendations
The American College of Obstetricians and Gynecologists (ACOG) has issued its own vaccine recommendations for pregnant individuals, which differ from those provided by the Centers for Disease Control and Prevention (CDC). ACOG recommends four vaccines be routinely administered during pregnancy, with additional vaccines suggested under specific conditions. This recommendation is supported by 13 medical societies and health organizations. ACOG emphasizes the importance of providing clear, evidence-based information on maternal immunizations amid growing vaccine-related confusion.
STAT+: Pharmalittle: We’re reading about U.S. pressure on European drug prices, longer shortages, and more
The article reports that the number of prescription drug shortages in the U.S. decreased by 23% in 2025, continuing a trend of decline and reaching the lowest level since 2017. However, the duration of these shortages has increased significantly, with an average of 5.3 years compared to 4.3 years in 2024 and much longer than the two-year average in 2019. Nearly two-thirds of the out-of-stock medications had been in short supply for over three years, and 39% were unavailable for more than five years. The 75 drugs in short supply last year covered 130 different therapeutic categories.
US guidelines didn't feature drinking risks found in gov't commissioned study
A government-commissioned study on alcohol-related health risks, conducted under President Joe Biden's administration, was released independently after the previous Trump administration chose not to include its findings in updated dietary guidelines. The study, published in the Journal of Studies on Alcohol and Drugs, concluded that even moderate alcohol consumption increases the risk of premature death and over 200 diseases. Researchers criticized the Trump administration for not incorporating these findings into the guidelines, which only recommended 'less alcohol for better overall health.'
DOJ reaches second settlement on youth gender care
The article discusses two main topics: the Department of Justice reaching a second settlement related to youth gender care and developments in health-related news. It also touches on diabetes experts being expelled from a meeting for distributing critical material and the approval of a new sunscreen ingredient by the FDA.
STAT+: As the U.S. looks on, European countries feel growing pressure on drug prices
The article discusses the differing approaches taken by European countries regarding drug pricing, highlighting the U.K.'s move toward more industry-friendly policies and Germany's proposal to reduce healthcare spending and increase pharmaceutical fees. The piece notes the impact of these decisions on pharmaceutical companies and patients, as well as the role of external influences such as the U.S.
Are Republicans turning against medications for treating opioid addiction?
The article discusses concerns over the Trump administration's recent stance on medications used to treat opioid use disorder, following statements by Robert F. Kennedy Jr., the newly appointed health secretary, who emphasized the importance of these treatments. Public health experts and patient advocates have expressed alarm over the administration's shift in approach.
Opinion: ‘They all think I’m insane’: What it’s like to start medical residency at 72
Dawn Zuidgeest-Craft, a 72-year-old former neonatal nurse practitioner, began medical school at age 69 and is set to start her residency in family medicine. She discusses her journey, including the challenges of starting residency at an advanced age, such as navigating employment while on Medicare. The article highlights her personal motivations, including a conversation with her husband following his health scare, and includes references to her podcast interview and an associated essay.
Trump warns hundreds of hospitals of fines over missing price information
The Trump administration issued warning letters to over 500 hospitals for failing to comply with federal price transparency requirements, which the administration argues inflate healthcare costs unnecessarily. The Associated Press obtained a copy of the list of affected hospitals.
STAT+: Trump’s health care affordability czar takes aim at hospitals
The article discusses Trump's health care affordability czar targeting hospitals, but the main content appears to be behind a paywall. The visible text includes unrelated snippets such as a reference to RFK Jr.'s work hours and a mention of a suppressed study on alcohol consumption.
Gilead and Merck’s latest trial success and flop
This article discusses two pharmaceutical developments: GlaxoSmithKline's acquisition of Nuvalent, a biotechnology firm with promising cancer treatments under FDA review, and a new weekly HIV treatment developed by Gilead and Merck that showed success in clinical trials.
STAT+: NIAID appoints new acting director after weekslong questions over leadership
The National Institutes of Health (NIH) has appointed John Powers III as the acting director of its infectious disease institute, following weeks of uncertainty after the departure of previous director Jeffery Taubenberger. Powers, who previously served as a senior adviser and deputy to Taubenberger, brings experience in clinical infectious diseases, clinical research, regulatory science, and public health leadership. This appointment comes amid concerns about the depth of infectious disease expertise available during ongoing outbreaks such as hantavirus and Ebola in Central Africa.
STAT+: Pharmalittle: We’re reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more
GlaxoSmithKline (GSK) has agreed to acquire Nuvalent, a cancer drug developer, in a $10.6 billion deal. Nuvalent is developing targeted cancer therapies, with two molecules currently under FDA review for non-small cell lung cancer. The acquisition is part of a broader trend in the biopharma industry, where companies are expanding their pipelines amid pressure from generic competition.
Dexcom RCT suggests CGM benefits for broad diabetes population
The article discusses recent developments in health technology, focusing on wearable devices like Oura and Whoop integrating access to virtual care providers into their apps. It also mentions the author's personal experience using multiple wearable health devices during a wellness checkup, highlighting the limited engagement with such technologies by healthcare professionals.
STAT+: Trump’s health care affordability czar touts Medicaid cuts to hospital leaders
At a healthcare conference, Casey Mulligan, Trump's health care affordability czar, advocated for significant Medicaid cuts outlined in the One Big Beautiful Bill Act. These cuts could save $510 billion over 10 years but would impact state-directed payments to hospitals and other providers. Mulligan praised these proposals during his speech.
Opinion: Ending animal testing could set back xenotransplantation just as the field is poised for a breakthrough
The article discusses the potential impact of ending federal funding for animal testing on the development of xenotransplantation, a field showing promise for medical breakthroughs. It references actions taken by the CDC and NIH, such as phasing out primate studies and reducing funding for animal models. The piece highlights arguments against animal testing, citing ethical concerns and the unreliability of animal models in predicting human health outcomes. It also mentions alternative methods like organ-on-a-chip technology and AI-driven models as possible replacements.
Opinion: Why STAT is sticking with ‘health care’ as two words
STAT News has decided to retain the term 'health care' as two words in its writing, despite the Associated Press Stylebook's recent shift to 'healthcare' as one word. The decision was based on the belief that using two words emphasizes the distinction between 'health' and 'care,' and highlights the variety of care types within the healthcare industry. While the healthcare sector has largely adopted the single-word form, STAT chose to maintain consistency with its long-standing style.
STAT+: Wearables, and the flood of data they generate, inch closer to entering the clinic
Wearable devices like smartwatches and rings are increasingly capable of detecting potential health issues, but integrating their data into clinical care remains challenging. Companies such as Oura and Whoop have introduced features allowing users to connect with doctors directly through their apps. However, experts note that the standards for using wearable data in medical decisions are much stricter than for general wellness tracking. The FDA has approved only a limited number of wearable features for clinical use, and there is currently insufficient evidence to support widespread relianceon